Emergence of High-Avidity Melan-A–Specific Q2 Clonotypes as a Reflection of Anti–PD-1 Q3 Clinical Efficacy

Abstract : Therapeutic strategies using anti-PD-1-blocking antibodies reported unparalleled effectiveness for melanoma immunotherapy, but deciphering immune responses modulated by anti-PD-1 treatment remains a crucial issue. Here, we analyzed the composition and functions of the large Melan-A-specific T-cell repertoire in the peripheral blood of 9 melanoma patients before and after 2 months of treatment with anti-PD-1. We observed amplification of Melan-A-specific Vß subfamilies undetectable before therapy (thereafter called emerging Vß subfamilies) in responding patients, with a predominant expansion in patients with a complete response. These emerging Vß subfamilies displayed a higher functional avidity for their cognate antigen than Vß subfamilies not amplified upon anti-PD-1 therapy and could be identified by a sustained coexpression of PD-1 and TIGIT receptors. Thus, in addition to the emergence of neoantigen-specific T cells previously documented upon anti-PD-1 therapy, our work describes the emergence of high-avidity Melan-A-specific clonotypes as a surrogate marker of treatment efficacy.
Document type :
Journal articles
Complete list of metadatas

Cited literature [47 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01636933
Contributor : Elizabeth Bernardo <>
Submitted on : Thursday, January 25, 2018 - 11:52:36 AM
Last modification on : Thursday, July 25, 2019 - 10:22:59 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Sylvain Simon, Virginie Vignard, Emilie Varey, Tiphaine Parrot, Anne-Chantal Knol, et al.. Emergence of High-Avidity Melan-A–Specific Q2 Clonotypes as a Reflection of Anti–PD-1 Q3 Clinical Efficacy. Cancer Research, American Association for Cancer Research, 2017, 77 (24), pp.7083 - 7093. ⟨10.1158/0008-5472.CAN-17-1856⟩. ⟨inserm-01636933v2⟩

Share

Metrics

Record views

179